Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 in Progressive Supranuclear Palsy
NCT05819658Phase 2Completed
- Sponsor
- GemVax & KAEL Co., Ltd.
- Start
- Jun 2023
- Primary completion
- Oct 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tertomotide in progressive supranuclear palsy (PSP), sponsored by GemVax & KAEL Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
tertomotide
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT05819658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05819658.